N4-胆固醇-精胺 | 179075-30-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: N4-胆固醇-精胺
• 中文别名: N4-精氨胆固醇羰酰氨(GL67)
• 英文名称: N4-Spermine cholesterol carbamate
• 英文别名: [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] N-(3-aminopropyl)-N-[4-(3-aminopropylamino)butyl]carbamate
• CAS: 179075-30-0
• 化学式: C₃₈H₇₀N₄O₂
• 分子量: 615.0
• InChiKey: KBBLYWGVXTZWCU-HMVYLTCSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  44
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  93.6
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• WGK Germany：
  3

文献信息

• LIPID ASSEMBLIES COMPRISING ANIONIC LYSOLIPIDS AND USE THEREOF
  申请人：Biomedical Research Foundation of the Academy of Athens

  公开号：EP2892505A1

  公开（公告）日：2015-07-15
• US9730893B2
  申请人：——

  公开号：US9730893B2

  公开（公告）日：2017-08-15
• [EN] LIPID ASSEMBLIES COMPRISING ANIONIC LYSOLIPIDS AND USE THEREOF<br/>[FR] ENSEMBLES LIPIDES COMPRENANT DES LYSOLIPIDES ANIONIQUES ET LEUR UTILISATION
  申请人：BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS

  公开号：WO2014037436A1

  公开（公告）日：2014-03-13

  The present invention relates to lipid assemblies, compositions, and liposomal delivery systems comprising single chain anionic lipids, and the use thereof in diagnosis and therapy. It involves the use of anionic lysolipids for modifying the surface charge of a cationic lipid composition consisting at least one type of cationic lipid, optionally in combination with one or more neutral lipids and/or one or more anionic lipids.
• [EN] POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS<br/>[FR] POLYNUCLÉOTIDES CODANT POUR UN RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE LA MUCOVISCIDOSE POUR LE TRAITEMENT DE LA MUCOVISCIDOSE
  申请人：[en]MODERNATX, INC.

  公开号：WO2022104131A1

  公开（公告）日：2022-05-19

  This disclosure relates to delivery vehicles comprising payload molecules, e.g., mRNA or gene editing therapeutics for the treatment of cystic fibrosis (CF). Nucleic acid therapeutics (e.g., mRNAs) for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR). Nucleic acid therapeutics (e.g., mRNAs) of the disclosure increase and/or restore deficient levels of CFTR expression and/or activity in subjects. Nucleic acid therapeutics (e.g., mRNAs) of the disclosure further decrease abnormal accumulation of ammonia associated with deficient CFTR activity in subjects.